Evercore ISI Highlights Dupixent and Eylea HD as Key Growth Drivers For Regeneron Pharmaceuticals, Inc. (REGN)

We recently compiled a list of the 20 Most Profitable Stocks of the Last 20 Years. Regeneron Pharmaceuticals, Inc. is among the most profitable stocks.

TheFly reported on January 22 that Evercore ISI increased its price target for REGN to $875 from $750 and maintained an Outperform rating on the stock. The firm expressed confidence in REGN’s updated outlook and recent pricing actions. Evercore ISI identified Dupixent and Eylea HD as key players in the company’s growth and noted that both products are well-positioned to sustain current competitiveness and improve future performance.

Evercore ISI Highlights Dupixent and Eylea HD as Key Growth Drivers For Regeneron Pharmaceuticals, Inc. (REGN)

Similarly, earlier this month, on January 8, Goldman Sachs also raised its price target for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $914 from $807 and gave it a Buy rating. The firm cited strong sector performance in 2025 and expects the positive momentum to continue into 2026, which is supported by favorable market conditions, easing policy risks, and potential M&A activity.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company specializing in the discovery, development, and commercialization of innovative medicines for serious diseases.

While we acknowledge the risk and potential of REGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than REGN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.